Antibodies or antigen-binding fragments thereof are engineered to bind Transforming Growth Factor-² (TGF²). TGF²-isoform selective antibodies or antigen-binding fragments thereof may selectively bind human TGF²1 compared to human TGF²2 and human TGF²3, or may selectively bind human TGF²3, compared to human TGF²1 and human TGF²2. The design of the antibodies or antigen-binding fragments thereof is facilitated by a co-crystal structure of a recombinant Fab fragment of GC1008 bound to TGF²2 and by another co-crystal structure of the scFv version of GC1008 bound to TGF²1.